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Molecular autopsy by trio exome sequencing (ES) and
postmortem examination in fetuses and neonates with
prenatally identified structural anomalies
Elizabeth Quinlan-Jones, MSc1,2, Jenny Lord, PhD3, Denise Williams, FRCP MSc1, Sue Hamilton, BSc4,
Tamas Marton, FRCPath PhD5, Ruth Y. Eberhardt, PhD3, Gabriele Rinck, PhD3, Elena Prigmore, PhD3,
Rebecca Keelagher, PhD4, Dominic J. McMullan, FRCPath4, Eamonn R. Maher, MD FRCP6,
Matthew E. Hurles, PhD FMedSci3 and Mark D. Kilby, DSc MD2,7
Purpose: To determine the diagnostic yield of combined exome
sequencing (ES) and autopsy in fetuses/neonates with prenatally
identified structural anomalies resulting in termination of preg-
nancy, intrauterine, neonatal, or early infant death.
Methods: ES was undertaken in 27 proband/parent trios following
full autopsy. Candidate pathogenic variants were classified by a
multidisciplinary clinical review panel using American College of
Medical Genetics and Genomics (ACMG) guidelines.
Results: A genetic diagnosis was established in ten cases (37%).
Pathogenic/likely pathogenic variants were identified in nine
different genes including four de novo autosomal dominant, three
homozygous autosomal recessive, two compound heterozygous
autosomal recessive, and one X-linked. KMT2D variants (associated
with Kabuki syndrome postnatally) occurred in two cases.
Pathogenic variants were identified in 5/13 (38%) cases with
multisystem anomalies, in 2/4 (50%) cases with fetal akinesia
deformation sequence, and in 1/4 (25%) cases each with cardiac
and brain anomalies and hydrops fetalis. No pathogenic variants
were detected in fetuses with genitourinary (1), skeletal (1), or
abdominal (1) abnormalities.
Conclusion: This cohort demonstrates the clinical utility of
molecular autopsy with ES to identify an underlying genetic cause
in structurally abnormal fetuses/neonates. These molecular findings
provided parents with an explanation of the developmental
abnormality, delineated the recurrence risks, and assisted the
management of subsequent pregnancies.
Genetics in Medicine (2018) https://doi.org/10.1038/s41436-018-
0298-8
Keywords: exome sequencing; fetuses; neonates; autopsy;
genetic diagnosis
INTRODUCTION
Fetal structural anomalies (FSAs) complicate 3% of pregnan-
cies and range in phenotype from isolated minor anomalies to
severe multisystem abnormalities, many of which are
associated with high perinatal mortality rates, or contribute
to long-term morbidity.1 Currently, such pregnancies may be
investigated prenatally by chorionic villus sampling (CVS) or
amniocentesis, to obtain fetal DNA for quantitative
fluorescent–polymerase chain reaction (QF-PCR) to exclude
common autosomal and sex chromosome aneuploidies, and
chromosomal microarray (CMA) to detect submicroscopic
copy-number variations (CNVs).2,3 Adding CMA analysis to
G-banded karyotyping increases the detection rate in this
group of fetuses by up to 5% (ref. 4). However, no identifiable
genetic cause is detected in over 60% of cases.5 If the
pregnancy is terminated or fetal demise occurs, autopsy is
important because despite generally good correlation between
prenatal ultrasound and autopsy findings, the latter can
identify additional subtle malformations and may elucidate
further information allowing an etiologic diagnosis necessary
for accurate genetic counseling.6,7
Exome sequencing (ES) is an established diagnostic tool in
delineating the genetic etiology of congenital abnormalities
and neurodevelopmental disorders8,9 in adults and children.
The use of ES for the analysis of prenatally obtained fetal
DNA has been reported in small cohort series and a recent
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review has indicated that this technology reveals pathogenic
findings in a range of between 6.2% and 80% of cases.10 Our
group has reported prospective data on 610 prenatal cases
with a spectrum of fetal anomalies detected by ultrasound
scan (USS) and demonstrated a diagnostic yield of 8.5% (95%
confidence interval [CI]: 6.4–11.0%); a further 3.9% had a
variant of uncertain significance (VUS) with potential clinical
value.11
One of the limitations in the use of prenatal ES is a lack of
accurate fetal phenotyping using prenatal ultrasonography
alone.10 In the cases of FSA ending in fetal demise, postnatal
dysmorphological examination and autopsy in addition to
prenatal ultrasound might be predicted to improve the
interpretation of genetic findings and increase diagnostic
yield. We have evaluated this in a cohort of fetuses/neonates
(n= 27). We correlated the results of ES from
proband–parent trios with prenatal USS and autopsy findings
to determine the clinical utility of molecular autopsy. Our
study supports the use of trio ES and autopsy to identify the
underlying etiology of structural anomalies, expand knowl-
edge of the genetic basis of fetal development, and enable
improved descriptions of phenotypic variation of known
genetic disorders.12
MATERIALS AND METHODS
Recruitment of cases
Parents of fetuses/neonates (n= 27) with a significant
structural anomaly resulting in termination of pregnancy
(TOP), intrauterine fetal demise (IUFD), or neonatal/infant
death (NND/ID) were identified by clinical geneticists,
perinatal pathologists, and fetal medicine specialists at
Birmingham Women’s and Children’s NHS Foundation Trust
(BWCNFT) and recruited to this study between May 2015
and December 2017. Prospectively obtained fetal DNA at
autopsy was stored at West Midlands Regional Genetics
Laboratory (WMRGL) and, with written consent, trio
(proband/biparental) ES was performed at the Wellcome
Sanger Institute (WSI) in Cambridge, United Kingdom. All
cases had previously undergone standard testing for aneu-
ploidy (QF-PCR) and whole-genome copy-number analysis
by CMA with no pathogenic abnormalities found. Parents
were prospectively informed that only results relevant to the
USS-detected FSA would be reported back (i.e., not secondary
findings). Ethics approval to undertake the research was
granted by National Research Ethics Service (NRES) Com-
mittee West Midlands–South Birmingham (ref: 13/WM/
1219). NHS Trust approval was provided by
BWCNFT–Research and Development Department.
Exome sequencing, variant calling, and annotation
In 26 cases DNA was extracted directly from fetal tissue
obtained at autopsy, and in one case fetal DNA was extracted
from cultured amniocytes obtained prenatally. The autopsy
tissue used to extract DNA varied from case to case and
included skin, lung, liver, and muscle. Parental DNA was
obtained from blood or saliva samples to form proband/
parent trios. Trio DNA samples were batched at WMRGL and
transferred to the WSI (Cambridge, UK) for ES through the
PAGE Study13 sequencing pipeline. For full information on
sequencing and analysis see Supplementary Methods. Briefly,
125 ng genomic DNA was fragmented (~150 bp) and library
preparation was conducted following Illumina’s standard
methodologies. Indexed libraries were pooled and exome
capture undertaken with the Agilent SureSelect XT Human
All Exon V5 Plus with custom ELID#0337431 (Agilent
Technologies, Santa Clara, CA, USA). Seventy-five base
paired-end sequencing (with six samples per lane on Illumina
HiSeq 2500) was conducted following the manufacturer’s
instructions, with over 97% of exonic positions having depth
of coverage >13×. Mapping was conducted with the
Burrows–Wheeler Aligner (BWA, version 0.59). Single-
nucleotide variants (SNVs) and indels were identified using
GATK HaplotypeCaller version 3.6 (ref. 14), while DeNovo-
Gear15 was used to identify de novo variants, and CoNVex
(http://www.uk10k.org/assets/ashg_vijayarangakannan_etal_
2012.pdf) and CIFER (https://github.com/jeremymcrae/cifer)
were used to identify and assess the inheritance of CNVs.
Variant call format (VCF) files were annotated using
Ensembl’s Variant Effect Predictor (VEP).16 Variants were
filtered to identify those of potential clinical significance based
on functional consequence (i.e., protein altering variants) and
minor allele frequency (MAF) across a number of resources
(see Supplementary Methods) (MAF > 0.005 excluded, with
more stringent filters applied for variants in monoallelic genes
[MAF >0.0005 excluded if both parents' data present]). The
analysis pipeline produced a selection of candidate pathogenic
variants with an inheritance pattern consistent with diseases
associated with the gene in question, and were filtered using a
modified developmental disorder–associated gene panel. A
virtual gene panel was used to maximize diagnostic yield and
minimize the potential for secondary findings, and high
numbers of variants of uncertain significance. This modified
gene panel included the full DDG2P gene list17 (https://www.
ebi.ac.uk/gene2phenotype) with several genes removed due to
the absence of a prenatal phenotype, as well as some
additional genes known to be associated with fetal develop-
ment sourced from the literature (see Supplementary Table 1).
Sequencing data is available from the European Genome-
phenome Archive (https://www.ebi.ac.uk/ega/).
Variant interpretation and classification
A multidisciplinary clinical review panel (CRP) comprising
clinical geneticists, fetal medicine specialists, perinatal pathol-
ogists, clinical scientists, midwives, and bioinformaticians
reviewed and classified candidate pathogenic variants.11
Through consensus agreement variants were classified using
the American College of Medical Genetics and Genomics
(ACMG) guidelines.18 Pathogenic and likely pathogenic
variants were further classified as to whether they explained
the observed phenotype fully, partially, or did not explain the
phenotype.18 The autopsies were carried out at West
Midlands Regional Perinatal Pathology Service (located
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within a tertiary, teaching hospital setting) by designated
subspecialty perinatal pathologists after informed consent was
sought from parents. In all cases a full autopsy was performed
according to Royal College of Pathologists guidelines,19,20
which included external examination, X-ray, comprehensive
internal examination, and histology of relevant internal
organs. Abnormal findings were photographically documen-
ted and discussed with senior clinical geneticists at a regular
dysmorphology meeting. Pathogenic/likely pathogenic var-
iants assessed to be causative for the observed fetal phenotype
were confirmed by Sanger sequencing. Reports were issued to
the clinical geneticist/fetal medicine specialist involved in the
care of the family to return the findings.
Statistical analysis
Fisher’s exact test was used to compare the diagnostic rates
and the number of homozygous autosomal recessive diag-
noses between cases with and without self-reported con-
sanguinity using R (version 3.1.3).
RESULTS
Demographic characteristics
The median age of women recruited was 30 years (95% CI
27.4–31.4). Nine (33%) women were nulliparous and 18
(67%) were multiparous. Gestational age (GA) at delivery
ranged from 15 to 35 weeks (median GA 23 weeks) (95% CI
21.4–28.8). In five pregnancies (19%) the women had a
previous history of a baby with a congenital malformation and
in six pregnancies (22%) there was parental consanguinity.
There were 15 (55%) TOP, 8 (30%) IUFD, and 4 (15%) NND/
ID. Gestational age ranged from 15 to 35 weeks (TOP), 16 to
34 weeks (IUFD), and 0 to 58 days postnatal (NND/ID).
There was no correlation between the presence of a diagnostic
ES finding and maternal age, ethnicity, parity, or GA.
Pregnancy outcome per proband according to phenotype
class (determined at postmortem [PM] examination) is
presented in Supplementary Figure 1.
Phenotype classification
Phenotypic information was obtained from the prenatal
imaging (USS and fetal magnetic resonance image [MRI])
reports, and from the final autopsy report. Initially, the 27
probands (10 female, 17 male) were categorized by phenotype
into 12 classes according to the anatomical system affected,
jointly by the fetal medicine specialist and clinical geneticist at
the study site. Following this, the perinatal pathologist also
independently categorized the cases according to the same
criteria (Tables 1 and 2). This resulted in the reclassification
of 4 fetal phenotypes (15%), increasing the number of brain (1
to 3) and abdominal (0 to 1) phenotypes, and reducing the
number of fetal akinesia deformation sequence (FADS) (4 to
3), genitourinary (2 to 1), and multisystem (14 to 13)
phenotypes; the cases of cardiac (4), skeletal (1), and hydrops
fetalis (1) remained unchanged. Reclassification of four cases
by the perinatal pathologist according to the autopsy findings
occurred for the following indications. Case 12 (see Table 2)
was an isolated omphalocele with no associated ventriculo-
megaly (VM) noted at autopsy and was therefore reclassified
as an isolated abdominal malformation. Prenatally it was
reported that the lateral ventricles measured just over 10 mm
bilaterally inferring “borderline” VM as an ultrasound
finding. It is possible that the VM was present and
subsequently resolved with advancing gestation. However, it
has been described that autopsy may fail to confirm VM
identified prenatally in approximately 50% of cases due to
resolution rather than autopsy artifact.21 Case 15 had a brain
abnormality identified prenatally (see Table 2), and subtle
skull, facial, and cardiac abnormalities confirmed at autopsy.
It was concluded that the additional anomalies observed
postnatally were subsequent to the primary brain anomaly
and thus the phenotype was reclassified from multisystem to
brain. The autopsy examination for case 19 (see Table 2)
identified internal genital and vertebral anomalies in addition
to the renal malformations diagnosed on prenatal ultrasound,
and hence it was reclassified from renal to multisystem.
Finally in case 23 (see Table 2) the observed FADS was
determined as having been caused by an underlying central
nervous system abnormality and was therefore reclassified to
the brain abnormality group. Almost half (13 cases) were
classified as having structural anomalies affecting multiple
organ systems. The remaining were classified as cardiac (4),
FADS (3), brain (3), genitourinary (1), skeletal (1), abdominal
(1), and hydrops fetalis (1) with no other structural
abnormality. There were no cases with isolated facial, chest,
or spinal anomalies, or raised nuchal translucency (NT) >4
mm (i.e., the minimum measurement required a priori to be
eligible for enrollment in the study).
Variant assessment
After bioinformatic filtering, 22 rare variants relating to 17
potential diagnoses in 15 probands were reviewed by the CRP.
In the remaining 12 individuals no candidate pathogenic
variants were identified. The mean number of variants
identified per case was 1.47 (range 1–3) for the 15 cases with
variants to review, and 0.815 across the entire cohort of 27
(Fig. 1). Variants were assessed in 16 different genes known to
be associated with various developmental disorders. Of the 15
cases, 13 had variants to review in a single gene (heterozygous
[6], compound heterozygous [4], or homozygous [3]) and 2
fetuses harbored homozygous or compound heterozygous
variants in two different genes.
Pathogenic variants
Of the 15 fetuses reviewed by the CRP, 10 were found to be
harboring pathogenic/likely pathogenic variants determined
to have fully/partially contributed to the phenotype observed
on prenatal USS and autopsy, giving a diagnostic rate of 37%
(Table 1). Four of the ten pathogenic variants had arisen de
novo (two cases with protein truncating variants in KMT2D,
and one case each with missense variants in PIK3R2 and
RIT1). The remaining pathogenic variants were inherited,
including a maternally inherited FOXP3 missense variant in a
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Table 2 Exome sequencing (ES) nondiagnostic cases
Proband
ID
Prenatal USS findings PM findings Phenotype
classification
based upon USS
and PM
1 NT measurement 4.0 mm, arthrogryposis Skin webs, flexed contractures, severe bilateral talipes,
webbed neck, micrognathia, reduced muscle bulk,
subcutaneous edema
FADS
2 Asymmetrical ventriculomegaly (displacement of the
midline), irregularity of the ventricular lining (possibly
neuronal heterotopias), possibly absent corpus callosum,
abnormal posterior fossa, single outlet to the heart, VSD
Large cranial vault, TOF, persistent left SVC, right-sided
aortic arch, absent right umbilical artery, abnormally
shaped thymus, severe dysplasia of the cerebellum with
obliteration of the 4th ventricle, malformed brainstem
and midbrain, atresia of aqueduct of Sylvius and 4th
ventricle, enlarged right cerebral hemisphere, probable
arachnoid cyst between hemispheres, abnormal deep
white matter bundles in cerebral hemispheres
Multisystem
4 Short long bones and talipes Small size, facial dysmorphia, prominent occiput, bilateral
talipes, rhizomelic shortening of the limbs, wide-set
nipples, osteopenic bones, horizontal ribs
Skeletal
5 Hydrops fetalis Facial dysmorphia, nuchal edema, dilated left atrium and
left ventricle, cardiomegaly, valvular aortic atresia
Cardiac
6 Small left ventricle, bilateral superior vena cavas,
levocardia with significant ventricular imbalance, small
slit-like left ventricle with some mitral inflow,
perimembranous VSD, normal large vessels, HLHS
Ebstein-type abnormality, DORV, abnormal left kidney
Overlapping fingers, bilateral talipes, dysmorphic ears,
skin webbed neck, cardiomegaly, pulmonary stenosis
with dysplastic valves, VSD, right ventricular pouch,
persistent left SVC, small testis/thymus, ectopic left
kidney
Multisystem
7 Polyhydramnios, micrognathia, right-side mild dilatation
of the renal pelvis
Facial dysmorphia, hypoplastic lungs, CPAM-0, small gall
bladder, small right kidney with dilated renal pelvis,
simple renal cysts bilaterally, gracile bones (especially the
clavicles, fracture of the right clavicle), excess of
extramedullary hematopoiesis in the liver
Multisystem
12 Exomphalos, borderline ventriculomegaly Omphalocele, bilateral talipes Abdominal
13 Bilateral multicystic, dysplastic kidneys Facial dysmorphia, pterygium of the neck, contractures of
the upper limbs, bilateral talipes, transverse palmar
creases, bilateral cystic–dysplastic kidneys, lung
hypoplasia
Genitourinary
14 Growth restriction <10th centile Retrognathia, ASD (secundum type), small thymus, lung
petechiae, distended bladder with retained urine (no
evidence of obstruction)
Cardiac
15 Unilateral ventriculomegaly Macrocephaly, partly compressed skull, overlapping
cranial bones, loose scalp, anteverted nares, small heart
Brain
17 Normal Micrognathia, omphalocele, bilateral talipes, bilaterally
three lobed lungs, irregularly shaped left kidney, cervical
ribs
Multisystem
18 Long narrow chest, heart in unusual orientation, single
multicystic dysplastic kidney, unilateral talipes, umbilical
vein varix, minimal liquor
Facial dysmorphia, left-side talipes, caudal orientation of
the heart, aortic valve dysplasia, rectal atresia, multicystic/
aplastic renal dysplasia, lumbar and sacral vertebrae
defects
Multisystem
19 Oligohydramnios, unilateral talipes,?absent bladder and
kidneys, IUGR
Potter syndrome, bilateral talipes, malpositioned anus,
transverse palmar creases (right hand), epicanthus, renal
agenesis, unicornuate uterus, lung hypoplasia,
irregularities of the sacrum vertebrae
Multisystem
20 Normal Unilateral talipes, complete AV channel, DORV,
pulmonary stenosis, symmetrical liver, absent gall
Multisystem
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male fetus, and three cases with recessively inherited
homozygous variants (including a missense variant in RAPSN,
and protein truncating variants in ERCC5 and CPT2). The
final two cases had biparentally inherited compound hetero-
zygous variants (a paternally inherited missense variant and a
maternally inherited protein truncating variant in PIGN, and
two different biparentally inherited protein truncating
variants in DNAH5). The diagnostic yield across different
phenotypic classes is presented in Fig. 2 (based on PM
classification). KMT2D gene alterations were determined to
be diagnostic in two separate individuals, thus, Kabuki
syndrome was the most common diagnosis.
In 6 cases out of the full cohort (n= 27), parental
consanguinity was recorded. The diagnostic yield was
increased in cases with recorded consanguinity (3/6; 50%)
as compared with those without consanguinity (7/21; 33%);
however this was not statistically significant (Fisher’s exact p
value= 0.6382). The types of diagnoses did differ however,
with all three diagnoses in the consanguineous cases being
biparentally inherited homozygous recessive variants, com-
pared with none of the diagnoses in nonconsanguineous cases
(Fisher’s exact p value= 0.0083).
There were no variants determined to be pathogenic/likely
pathogenic but without relevance for the presenting fetal
phenotype. In total, ten VUS were identified relating to six
individual probands that were determined by the CRP to have
no relevance to the fetal phenotype in each case (see
Supplementary Table 2). Ethical approval for the study
restricted the disclosure of genetic findings to those that were
relevant to the FSA and thus these findings were not reported.
DISCUSSION
The genetic contribution to FSA is incompletely under-
stood,22 and evidence relating to the clinical utility of next-
generation sequencing (NGS) in the investigation of perinatal
loss and morbidity in fetuses with structural anomalies is
limited. Relatively small cohort studies have been published
and indicate that the use of NGS in the perinatal context gives
a diagnostic yield of 12–57% (refs. 12,22–24). However, such
publications describe a heterogeneous mix of prenatal
ultrasound diagnoses and autopsy findings in fetuses with
Table 2 continued
Proband
ID
Prenatal USS findings PM findings Phenotype
classification
based upon USS
and PM
bladder, right type isomerism of the lungs, auricles,
absent spleen, right-sided stomach
23 Polyhydramnios Abnormal posture of limbs (flexed legs in the hip and
pointy feet), ulnar deviation of the hands and flexed
thumbs, thin neck and diaphragm, lung hypoplasia, thin
ribs, Arnold–Chiari type II (no cerebellar hypoplasia or
spina bifida)
Brain
26 Congenital bladder neck obstruction Subcutaneous edema, scoliosis, talipes and skeletal
abnormalities, distended abdominal wall, anal atresia,
abnormal genitalia, bladder neck obstruction with cystic
bladder, rectal–vesical fistula, small lungs, small kidneys
and adrenals, cystic–dysplastic change in kidneys
associated to LUTO
Multisystem
27 HLHS HLHS, 11 pairs of ribs, low-set eyes Cardiac
ASD atrial septal defect, AV atrioventricular, CPAM congenital pulmonary airway malformation, DORV double outlet right ventricle, FADS fetal akinesia deformation
sequence, HLHS hypoplastic left heart syndrome, IUGR intrauterine growth restriction, LUTO lower urinary tract obstruction, NT nuchal translucency, PM postmortem,
SVC superior vena cava, TOF tetralogy of Fallot, USS ultrasound scan, VSD ventricular septal defect.
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Fig. 1 Number of potential clinical diagnoses per proband reviewed
by the clinical review panel (CRP).
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congenital structural anomalies. A recent study investigating
FSA described the use of prenatal samples negative for
karyotyping and CMA consented for ES, once a parental
decision on termination of pregnancy (TOP) was made. Of
the 15 fetuses studied, ES identified pathogenic variants in 7
(47%) cases providing a likely causative diagnosis.25 The
largest reported series to date performed ES in 84 deceased
fetuses with structural anomalies, 52 of which comprised
parental/fetus trios or quads. Where trio data were obtained a
diagnostic yield of 24% was made. In those probands with
only fetal DNA tested, there was a lower diagnostic rate of
14% (ref. 12). In a cohort of perinatal mortality cases (n= 50)
with limited availability of proband DNA, exome sequencing
of parental DNA was performed to identify heterozygous rare
variants under a shared model of inheritance.26 Utilization of
this novel strategy to diagnose recessive monogenic disorders
in parents (subsequently confirmed as cosegregating in the
affected fetus by targeted testing) demonstrated pathogenic/
likely pathogenic variants in 24 different genes in 26/50
couples (52%). Where two or more fetuses were affected a
genetic diagnosis was identified in 18/29 couples (62%),
leading the authors to conclude that this is a powerful
approach with high clinical utility for genetic diagnosis of
lethal or prenatal-onset recessive conditions. Our reported
diagnostic yield of 37% demonstrates further the value of trio
ES in combination with a detailed autopsy.
An underlying genetic etiology for the congenital structural
anomalies cannot usually be predicted accurately based on the
prenatal USS appearances alone.23 This is primarily because
the phenotype in the developing fetus is often inadequately
defined. For example, a recent retrospective study examined
the diagnostic utility and limitations of ES in prenatal cases
with structural birth defects. DNA from 20 trios (fetal and
parental), with normal karyotype and CMA findings, under-
went ES and variant interpretation.27 The ES results were later
reevaluated utilizing details of prenatal and postnatal
phenotyping. Initial analysis using only a clinical description
of prenatal ultrasound findings revealed no pathogenic/likely
pathogenic variants in the 20 pregnancies evaluated but
reanalysis with a combination of prenatal and postnatal
phenotyping yielded pathogenic variants in at least 20% of
cases.
In our series there was generally a very good association
between prenatal USS descriptions and autopsy findings (as
previously noted in a larger study from our group6). However
in four cases (Fig. 2), subtle findings identified on autopsy led
to a reclassification of the fetal phenotype. Though such
findings do not necessarily influence the working clinical
diagnosis (and as appertains to this cohort did not translate
into an increased incidence of pathogenic variants), additional
information available from autopsy can aid interpretation of
ES detected variants and increase diagnostic yield or help
exclude variants that come through the bioinformatics
filtering process but are unlikely to account for the relevant
FSA phenotype. In case 8 a homozygous missense substitution
in RAPSN (c.485A>G p.(Glu162Gly) was identified in a fetus
with a prenatal USS finding of fetal akinesia deformation
sequence and autopsy confirmed the presence features of
arthrogryposis multiplex. RAPSN encodes the receptor-
associated protein, rapsyn (RAPSN) involved in AChR
localization and assembly and localization of the postsynaptic
muscle nicotinic acetylcholine receptor. Recessively inherited
pathogenic variants in RAPSN were initially described in
individuals with congenital myasthenic syndrome28 and
subsequently with lethal fetal akinesia.29 Previously it has
been noted that early severe onset disease (fetal akinesia/
multiple pterygium syndrome) tended to be associated with
severe loss-of-function pathogenic variants and later-onset
myasthenic syndrome with missense substitutions causing
milder alterations of function.29,30 Though RAPSN missense
substitutions (as case 8) have been associated with severe
disease the availability of detailed information from the
autopsy (including lack of evidence for central nervous system
cause) contributed to a consensus classification of the variant
as likely pathogenic. In addition the combination of ES and a
more detailed autopsy phenotype can expand knowledge of
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the prenatal phenotype of developmental disorders and/or
rarer manifestations of severe cases. For example, case 25 was
found to have renal cystic dysplasia on prenatal ultrasono-
graphy and also demonstrated polymicrogyria of the central
nervous system with calcification. ES analysis revealed a
homozygous truncating CPT2 variant consistent with a
diagnosis of carnitine palmitoyltransferase (CPT) II defi-
ciency. Although this rare disorder typically presents with
myoglobinuria in adults or fasting hypoglycemia in children,
rarely severe cases may present prenatally.31 In a review of
19 such cases, cerebral calcification was noted in 3 cases and
polymicrogyria in 1 case.31 In cases in which ES was not
diagnostic, such as case 23, autopsy examination identified
abnormalities that were not identifiable on prenatal ultra-
sound and this refined the phenotypic abnormalities and
might facilitate future diagnosis. It is acknowledged, however,
that this cohort of cases were highly selected with a degree of
selection bias.
The genetic findings greatly assist assessment of recurrence
risk in future pregnancies. In the four cases with de novo
findings it was possible to reassure the parents of a low
recurrence risk. The parents with inherited diagnoses (6) were
counseled as to the likely risk of recurrence according to the
mode of inheritance in each individual case (case studies 1
and 2). Those with recurrence risks then had the option for
invasive prenatal diagnosis in a subsequent pregnancy to
ascertain if the fetus was affected with the same condition.
For the duration of this study the trio samples were
reanalyzed at five planned time points (data freezes) to
include recently identified genes, as well as new alterations in
known genes that associate with congenital malformation
(Supplementary Table 1). This resulted in the detection of
pathogenic variants in two fetuses that previously lacked a
genetic diagnosis, in case 25 (CPT2 stop gained mutation) and
case 11 (DNAH5 compound heterozygous frameshift/stop
gained mutations). Both genes were added into the virtual
gene panel after the initial review of the fetuses, demonstrat-
ing the strength of our iterative analysis approach. The added
value of systematic review of ES data in the light of new
knowledge has been shown to significantly improve diag-
nostic yield in the context of the Deciphering Developmental
Disorders study.17 Through improved variant calling meth-
ods, novel variant detection algorithms, updated variant
annotation, evidence-based filtering strategies, and newly
discovered disease-associated genes, diagnostic yield in a
pediatric cohort with clinically diagnosed development delay
was increased by 13% (from 27% to 40%). This raises the
importance of reanalysis of perinatal sequencing data in
relation to ongoing genetic diagnosis, and demonstrates the
need for further research as to the potential added value of
genomic reanalysis in undiagnosed fetal and neonatal
mortality cases.
Our findings therefore support the routine use of molecular
autopsy using trio ES and full autopsy to investigate perinatal
loss and elucidate the underlying genetic basis of structural
developmental abnormality, particularly in relation to severe
“lethal” fetal phenotypes where the ethical issues that cause
concern with testing in an ongoing pregnancy are somewhat
ameliorated in pregnancies that have already ended.
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